- Home
- TRML vs EYPT Comparison
TRML vs EYPT Comparison
Compare TRML & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRML
- EYPT
- Stock Information
- Founded
- TRML 2021
- EYPT 1987
- Country
- TRML United States
- EYPT United States
- Employees
- TRML N/A
- EYPT N/A
- Industry
- TRML Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- TRML Health Care
- EYPT Industrials
- Exchange
- TRML Nasdaq
- EYPT Nasdaq
- Market Cap
- TRML 419.1M
- EYPT 439.4M
- IPO Year
- TRML N/A
- EYPT 2005
- Fundamental
- Price
- TRML $23.01
- EYPT $8.95
- Analyst Decision
- TRML Strong Buy
- EYPT Strong Buy
- Analyst Count
- TRML 3
- EYPT 8
- Target Price
- TRML $65.00
- EYPT $27.29
- AVG Volume (30 Days)
- TRML 187.7K
- EYPT 1.4M
- Earning Date
- TRML 11-07-2024
- EYPT 11-07-2024
- Dividend Yield
- TRML N/A
- EYPT N/A
- EPS Growth
- TRML N/A
- EYPT N/A
- EPS
- TRML N/A
- EYPT N/A
- Revenue
- TRML N/A
- EYPT $45,713,000.00
- Revenue This Year
- TRML N/A
- EYPT N/A
- Revenue Next Year
- TRML N/A
- EYPT N/A
- P/E Ratio
- TRML N/A
- EYPT N/A
- Revenue Growth
- TRML N/A
- EYPT 7.50
- 52 Week Low
- TRML $12.12
- EYPT $5.87
- 52 Week High
- TRML $48.31
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- TRML 37.25
- EYPT 41.34
- Support Level
- TRML $25.58
- EYPT $8.25
- Resistance Level
- TRML $27.51
- EYPT $9.40
- Average True Range (ATR)
- TRML 1.81
- EYPT 0.83
- MACD
- TRML -0.61
- EYPT -0.38
- Stochastic Oscillator
- TRML 10.76
- EYPT 17.44
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.